Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 30370

Spleen peptides(polyerga(TM)) inhibit development of artificial lung metastases of Murine mammary carcinoma and increase efficiency chemotherapy in mice


Žarković, Neven; Hartleb, Martin; Žarković, Kamelija; Borović, Suzana; Golubić, Jasminka; Kališnik, Tea; Frech, Svenja; Klingmuller, Martin; Lončarić, Iva; Bošnjak, Berislav et al.
Spleen peptides(polyerga(TM)) inhibit development of artificial lung metastases of Murine mammary carcinoma and increase efficiency chemotherapy in mice // Cancer biotherapy & radiopharmaceuticals, 13 (1998), 1; 25-32 doi:10.1089/cbr.1998.13.25 (međunarodna recenzija, članak, znanstveni)


CROSBI ID: 30370 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
Spleen peptides(polyerga(TM)) inhibit development of artificial lung metastases of Murine mammary carcinoma and increase efficiency chemotherapy in mice

Autori
Žarković, Neven ; Hartleb, Martin ; Žarković, Kamelija ; Borović, Suzana ; Golubić, Jasminka ; Kališnik, Tea ; Frech, Svenja ; Klingmuller, Martin ; Lončarić, Iva ; Bošnjak, Berislav ; Jurin, Mislav ; Kuhlmey, Jurgen

Izvornik
Cancer biotherapy & radiopharmaceuticals (1084-9785) 13 (1998), 1; 25-32

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
mammary carcinoma ; cancer biotherapy ; spleen peptides ; chemotherapy

Sažetak
There are numerous attempts to find novel anticancer drugs or to improve therapeutic protocols based on application of chemotherapeutic agents and immunomodulators (biological response modifiers, cytokines, various plant or bacterial products). Among the preparations that have beneficial effects for the cancer bearing organism are preparations of spleen peptides (Polyerga(TM)). Hence, we analyzed if treatment with spleen oligopeptides GP-1 (active substance for the manufacture of Polyerga(TM) ampoules' solution injected as 0.5 mu g/kg every second day) if given alone or combined with chemotherapy (Endoxan 50 mg/kg single i.p. dose) of mice bearing artificial lung metastases of mammary carcinoma will have an impact on the metastases count and survival of the animals. The results obtained have shown that chemotherapy reduced metastases count and increased survival of the tumor bearing mice, while the use of GP-1 alone did not affect metastases development. However, combined GP-1 treatment and chemotherapy were more efficient in prevention of the metastases development than chemotherapy alone. Thus, in mice treated with GP-1 and Endoxan, the average metastases count was four times lower than in the mice treated by chemotherapy only, while 2/12 animals were without tumor nodules in the lungs. Finally, all the animals treated by chemotherapy alone died until the 42nd day after tumor transplantation, while at the same time, only 5/10 animals died receiving combined therapy. Thus, these results give an experimental support for the use of the spleen peptides in biotherapy (or combined therapy) of cancer. [References: 35]

Izvorni jezik
Engleski

Znanstvena područja
Kemija, Biologija, Temeljne medicinske znanosti



POVEZANOST RADA


Projekti:
108083
00981113

Ustanove:
Institut "Ruđer Bošković", Zagreb,
Medicinski fakultet, Zagreb

Poveznice na cjeloviti tekst rada:

doi www.liebertpub.com

Citiraj ovu publikaciju:

Žarković, Neven; Hartleb, Martin; Žarković, Kamelija; Borović, Suzana; Golubić, Jasminka; Kališnik, Tea; Frech, Svenja; Klingmuller, Martin; Lončarić, Iva; Bošnjak, Berislav et al.
Spleen peptides(polyerga(TM)) inhibit development of artificial lung metastases of Murine mammary carcinoma and increase efficiency chemotherapy in mice // Cancer biotherapy & radiopharmaceuticals, 13 (1998), 1; 25-32 doi:10.1089/cbr.1998.13.25 (međunarodna recenzija, članak, znanstveni)
Žarković, N., Hartleb, M., Žarković, K., Borović, S., Golubić, J., Kališnik, T., Frech, S., Klingmuller, M., Lončarić, I. & Bošnjak, B. (1998) Spleen peptides(polyerga(TM)) inhibit development of artificial lung metastases of Murine mammary carcinoma and increase efficiency chemotherapy in mice. Cancer biotherapy & radiopharmaceuticals, 13 (1), 25-32 doi:10.1089/cbr.1998.13.25.
@article{article, author = {\v{Z}arkovi\'{c}, Neven and Hartleb, Martin and \v{Z}arkovi\'{c}, Kamelija and Borovi\'{c}, Suzana and Golubi\'{c}, Jasminka and Kali\v{s}nik, Tea and Frech, Svenja and Klingmuller, Martin and Lon\v{c}ari\'{c}, Iva and Bo\v{s}njak, Berislav and Jurin, Mislav and Kuhlmey, Jurgen}, year = {1998}, pages = {25-32}, DOI = {10.1089/cbr.1998.13.25}, keywords = {mammary carcinoma, cancer biotherapy, spleen peptides, chemotherapy}, journal = {Cancer biotherapy and radiopharmaceuticals}, doi = {10.1089/cbr.1998.13.25}, volume = {13}, number = {1}, issn = {1084-9785}, title = {Spleen peptides(polyerga(TM)) inhibit development of artificial lung metastases of Murine mammary carcinoma and increase efficiency chemotherapy in mice}, keyword = {mammary carcinoma, cancer biotherapy, spleen peptides, chemotherapy} }
@article{article, author = {\v{Z}arkovi\'{c}, Neven and Hartleb, Martin and \v{Z}arkovi\'{c}, Kamelija and Borovi\'{c}, Suzana and Golubi\'{c}, Jasminka and Kali\v{s}nik, Tea and Frech, Svenja and Klingmuller, Martin and Lon\v{c}ari\'{c}, Iva and Bo\v{s}njak, Berislav and Jurin, Mislav and Kuhlmey, Jurgen}, year = {1998}, pages = {25-32}, DOI = {10.1089/cbr.1998.13.25}, keywords = {mammary carcinoma, cancer biotherapy, spleen peptides, chemotherapy}, journal = {Cancer biotherapy and radiopharmaceuticals}, doi = {10.1089/cbr.1998.13.25}, volume = {13}, number = {1}, issn = {1084-9785}, title = {Spleen peptides(polyerga(TM)) inhibit development of artificial lung metastases of Murine mammary carcinoma and increase efficiency chemotherapy in mice}, keyword = {mammary carcinoma, cancer biotherapy, spleen peptides, chemotherapy} }

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE


Citati:





    Contrast
    Increase Font
    Decrease Font
    Dyslexic Font